Design Therapeutics, Inc. (DSGN) Financial Analysis & Valuation | Quarter Chart
Design Therapeutics, Inc. (DSGN)
DSGNPrice: $10.73
Fair Value: 🔒
🔒score
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progr... more
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development ... more
Description
Shares
| Market Cap | $661.74M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Pratik Shah |
| IPO Date | 2021-03-29 | CAGR | — |
| Employees | 56 | Website | www.designtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.05% | Total Yield | -0.05% |
DSGN chart loading...
Fundamentals
Technicals
| Enterprise Value | $611.94M | P/E Ratio | -8.8 |
| Forward P/E | -7.65 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 3.95 |
| P/CF Ratio | -15.37 | P/FCF Ratio | -15.23 |
| EPS | $-1.22 | EPS Growth 1Y | 38.64% |
| EPS Growth 3Y | 15.09% | EPS Growth 5Y | 303.04% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.33% | ROA | -0.31% |
| ROCE | -0.37% | Current Ratio | 17.14 |
| Quick Ratio | 17.14 | Cash Ratio | 1.29 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 27.95 | Piotroski Score | 1 |